# Caplin Point Laboratories Limited (CAPLIPOINT)

> CAPLIPOINT closed at ₹2,331.00 on 30 Oct 2026, trailing P/E 26.6, market cap ₹17,716 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Caplin Point Laboratories Limited (NSE: CAPLIPOINT) closed at ₹2,331.00 on 30 Oct 2026, +17.3% over one year, against a 52-week range of ₹1,500.30 – ₹2,990.00.

In the quarter ended 30 Jun 2026 (consolidated, filed 12 Aug 2026) it reported revenue of ₹610 cr and net profit of ₹177 cr, a 29.0% net margin; revenue grew 19.6% and profit grew 22.1% year on year.

On four consecutive filed quarters its trailing P/E is 26.6; since 15 May 2025 its own P/E has ranged from 18.6 to 33.2 (median 28.4), and today's reading is higher than 31% of those 361 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 19.7%, ROCE 24.6%, debt-to-equity 0.00, Piotroski F-score 4 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 97% of 63 sector peers; PBT margin higher than 95% of 63 sector peers; ROE higher than 75% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹2,331.00 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -18.7% / +35.6% / +17.3% |
| 52-week low – high | ₹1,500.30 – ₹2,990.00 |
| Market capitalisation | ₹17,716 cr |
| Trailing P/E | 26.6 |
| Price / book | 4.94 |
| EV / EBITDA | 19.1 |
| Earnings yield | 3.8% |
| TTM EPS | ₹87.55 |
| TTM net profit | ₹665 cr |
| Quarter revenue | ₹610 cr |
| Quarter net profit | ₹177 cr |
| Net margin | 29.0% |
| Revenue growth (YoY) | +19.6% |
| Profit growth (YoY) | +22.1% |
| Return on equity | 19.7% |
| ROCE | 24.6% |
| Debt / equity | 0.00 |
| Current ratio | 6.70 |
| Free cash flow | ₹275 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹27.9 cr |

## Questions

### What is the P/E ratio of Caplin Point Laboratories Limited?

Caplin Point Laboratories Limited's trailing P/E is 26.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 15 May 2025 its P/E has ranged 18.6–33.2.

### What were Caplin Point Laboratories Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Caplin Point Laboratories Limited reported revenue of ₹610 cr and net profit of ₹177 cr (consolidated), filed with the exchange on 12 Aug 2026.

### What is Caplin Point Laboratories Limited's ROE?

Return on equity is 19.7% based on the balance sheet dated 31 Mar 2026.

### Does Caplin Point Laboratories Limited have debt?

Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.

### What is CAPLIPOINT's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, CAPLIPOINT traded between ₹1,500.30 and ₹2,990.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/CAPLIPOINT

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._